Cotinga Pharmaceuticals Inc COTQF

Healthcare Biotechnology

Cotinga Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's lead clinical candidate, COTI-2, is an oral small molecule targeting p53, a tumor suppressor gene that is mutated in over 50% of all cancers, and the company's second clinical candidate, COTI-219, is a novel oral small molecule compound targeting the mutant forms of KRAS with such mutations occurring in up to 30% of all cancers.

GREY:COTQF - Post by User

Cotinga Pharmaceuticals Inc

Bullboard Posts

Comment by valueforeveron Aug 08, 2013 6:46pm

243 Views

Post# 21657927

RE:increased interest in the sector?

who knows....i have owned this for a long time and it just seems that in the past couple of weeks (or months) there has been a definately increase in share volume, i think people just forgot about it after 2009. Its nice to see this volume but one has to remember that it doesn't even amount much over $100,000 dollar value. and these vse penny stocks can dive back to 15 cents in a heartbeat. as for their technology, who knows i ain't no rocket genius.If i remember right, from one of the last press releases i guess we are due for a special announcement from a major pharmaceutical....or from the company saying we have a partnership with "x"...if we don't i guess look out below.

Bullboard Posts

Advancing an underexplored area of the Yukon with the same geology as B.C’.s Golden Triangle